Exophthalmos treatment sales will strengthen through 2036, anchored by non-surgical treatments at 57.6% of the treatment segment in 2026. The market was valued at USD 271.8 million in 2025 and is expected to reach USD 640.2 million by 2036, creating an incremental opportunity of USD 346.4 million between 2026 and 2036.